Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency

JIANG Yan; ZHANG Ming; LIU Guoxin; ZHAO Chenyang

doi:10.6039/j.issn.1001-0408.2025.15.14

您当前的位置：

首页 >

文章列表页 >

Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency

更新时间：2025-11-14

- Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency
- ZHONGGUO YAOFANG Vol. 36, Issue 15, Pages: 1899-1903(2025)
- 作者机构：
  
  大连医科大学附属第二医院药学部，辽宁大连　116021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.15.14
  CLC： R969.4;R692.3+1
- Received：27 March 2025，
  
  Revised：2025-07-30，
  
  Accepted：30 July 2025，
  
  Published：15 August 2025
- 稿件说明：
移动端阅览
姜衍,张明,刘国鑫,等.黄葵胶囊联合环磷酰胺及泼尼松治疗肾功能不全IgA肾病的临床观察[J].中国药房,2025,36(15):1899-1903.

JIANG Yan,ZHANG Ming,LIU Guoxin,et al.Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency[J].ZHONGGUO YAOFANG,2025,36(15):1899-1903.
姜衍,张明,刘国鑫,等.黄葵胶囊联合环磷酰胺及泼尼松治疗肾功能不全IgA肾病的临床观察[J].中国药房,2025,36(15):1899-1903. DOI： 10.6039/j.issn.1001-0408.2025.15.14.

JIANG Yan,ZHANG Ming,LIU Guoxin,et al.Clinical observation of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of IgA nephropathy with renal insufficiency[J].ZHONGGUO YAOFANG,2025,36(15):1899-1903. DOI： 10.6039/j.issn.1001-0408.2025.15.14.

摘要

目的

探讨黄葵胶囊联合环磷酰胺及泼尼松治疗肾功能不全免疫球蛋白A（IgA）肾病的临床疗效及安全性。

方法

将2021年2月－2024年3月在大连医科大学附属第二医院肾内科住院治疗的117例肾功能不全IgA肾病患者按照随机数字表法分为泼尼松组（

＝38）、环磷酰胺组（

＝39）和黄葵组（

＝40）。3组患者在标准化基础治疗上，分别予以泼尼松、泼尼松+环磷酰胺、泼尼松+环磷酰胺+黄葵胶囊治疗，疗程均为6个月。比较3组患者的临床疗效和治疗前后肾功能指标、免疫球蛋白、炎症因子水平以及治疗期间不良反应发生情况。

结果

最终有107例患者（泼尼松组35例、环磷酰胺组37例、黄葵组35例）完成研究。治疗6个月后，3组患者的总有效率差异有统计学意义（

＝0.028），其中黄葵组的总有效率显著高于泼尼松组（

＝0.023）。在肾功能方面，3组患者治疗后的血尿素氮（BUN）、血肌酐（Scr）、尿微量白蛋白（Umalb）水平均较治疗前显著降低，估算肾小球滤过率（eGFR）均较治疗前显著升高（

＜0.05），其中黄葵组在降低BUN水平上优于其他两组（

＜0.05），而黄葵组与环磷酰胺组在改善Scr、Umalb、eGFR上均优于泼尼松组（

＜0.05）。免疫学方面，黄葵组与环磷酰胺组在升高IgG、降低IgA及IgM水平上均优于泼尼松组（

＜0.05）。炎症因子方面，黄葵组在降低肿瘤坏死因子α水平上优于泼尼松组与环磷酰胺组（

＜0.05），在降低白细胞介素6水平上优于泼尼松组（

＜0.05）。3组患者不良反应总发生率的差异无统计学意义（

＞0.05）。

结论

黄葵胶囊联合环磷酰胺及泼尼松治疗肾功能不全IgA肾病的疗效较好，可进一步改善患者肾功能和免疫功能、调控炎症状态，且安全性良好。

Abstract

OBJECTIVE

To explore the clinical efficacy and safety of Huangkui capsule combined with cyclophosphamide and prednisone in the treatment of immunoglobulin A （IgA） nephropathy with renal insufficiency.

METHODS

A total of 117 patients with IgA nephropathy and renal insufficiency who were hospitalized in the department of nephrology of the Second Affiliated Hospital of Dalian Medical University from February 2021 to March 2024 were divided into prednisone group （

＝38）， cyclophosphamide group （

＝39） and Huangkui group （

＝40） according to the random number table method. On the basis of standardized basic treatment， the three groups were treated with prednisone， prednisone + cyclophosphamide， and prednisone + cyclophosphamide + Huangkui capsule， respectively， with a course of 6 months. The clinical efficacy， renal function indexes， immunoglobulin levels， inflammatory factor levels before and after treatment， and the incidence of adverse reactions during treatment were compared among the three groups.

RESULTS

Finally， 107 patients completed the study （35 in prednisone group， 37 in cyclophosphamide group， and 35 in Huangkui group）. After 6 months of treatment， there was a statistically significant difference in the total effective rate among the three groups （

＝0.028）， and the total effective rate of the Huangkui group was significantly higher than that of the prednisone group （

＝0.023）. In terms of renal function， the levels of blood urea nitrogen （BUN）， serum creatinine （Scr）， and urinary microalbumin （Umalb） in the three groups after treatment were significantly lower than those before treatment， while the estimated glomerular filtration rate （eGFR） was significantly higher than that before treatment （

＜0.05）. Among them， the Huangkui group was superior to the other two groups in reducing BUN level （

＜0.05）， and both the Huangkui group and cyclophosphamide group were superior to the prednisone group in improving Scr， Umalb and eGFR （

＜0.05）. In terms of immunology， both the Huangkui group and

cyclophosphamide group were superior to the prednisone group in increasing IgG level and decreasing IgA and IgM levels （

＜0.05）. In terms of inflammatory factors， the Huangkui group was superior to the prednisone group and cyclophosphamide group in reducing tumor necrosis factor-α level （

＜0.05）， and superior to the prednisone group in reducing interleukin-6 level （

＜0.05）. There was no statistically significant difference in the total incidence of adverse reactions among the three groups （

＞0.05）.

CONCLUSIONS

Huangkui capsule combined with cyclophosphamide and prednisone has a good therapeutic effect on IgA nephropathy with renal insufficiency. It can further improve patients’ renal function and immune function， regulate inflammatory status， and has good safety.

关键词

Keywords

references

STAMELLOU E ， SEIKRIT C ， TANG S C W ， et al . IgA nephropathy [J ] . Nat Rev Dis Primers ， 2023 ， 9 ： 67 .

Kidney Disease ： Improving Global Outcomes CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J ] . Kidney Int ， 2024 ， 105 （ 4S ）： S117 - S314 .

LV J C ， WONG M G ， HLADUNEWICH M A ， et al . Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy：the TESTING randomized clinical trial [J ] . JAMA ， 2022 ， 327 （ 19 ）： 1888 - 1898 .

CASTER D J ， LAFAYETTE R A . The treatment of primary IgA nephropathy：change，change，change [J ] . Am J Kidney Dis ， 2024 ， 83 （ 2 ）： 229 - 240 .

刘毅，崔鑫，王福平，等 . 基于整合生物信息学探究黄葵胶囊治疗慢性肾脏病的机制 [J ] . 中药药理与临床， 2024 ， 40 （ 5 ）： 68 - 75 .

王福平，张蕾，吕健，等 . 基于Meta分析与整合生物信息学探究黄葵胶囊治疗慢性肾脏病的有效性、安全性及其机制 [J ] . 中国中药杂志， 2023 ， 48 （ 16 ）： 4493 - 4507 .

中国医药卫生文化协会肾病与血液净化专业委员会，李文歌，蒋更如，等 . 原发性IgA肾病管理和治疗中国专家共识 [J ] . 中华肾病研究电子杂志， 2024 ， 13 （ 1 ）： 1 - 8 .

王海燕，赵明辉 . 肾脏病学 [M ] . 4版 . 北京：人民卫生出版社， 2020 ： 1057 - 1064 .

ZHANG L ， WANG Y ， XU J ， et al . Abelmoschus manihot for primary glomerular disease：a meta-analysis of randomized controlled trials [J ] . J Altern Complement Med ， 2014 ， 20 （ 3 ）： 176 - 191 .

YUAN L L ， CAI K ， ZOU Y J . Clinical efficacy of Huangkui capsule plus methylprednisolone for immunoglobulin A nephropathy and its effect on renal function and serum inflammatory factors [J ] . Evid Based Complement Alternat Med ， 2023 ， 2023 ： 3020033 .

LAFAYETTE R A ， CANETTA P A ， ROVIN B H ， et al . A randomized，controlled trial of narsoplimab in patients with IgA nephropathy [J ] . J Am Soc Nephrol ， 2023 ， 34 （ 6 ）： 1096 - 1108 .

YE Q ， TANG S ， CHEN Y ， et al . IgM and C3 Co-deposition is a predictor of poor prognosis in IgA nephropathy [J ] . Kidney Dis （Basel）， 2022 ， 8 （ 2 ）： 159 - 168 .

GAO L ， ZHANG X ， YU D R ， et al . Relationship between IgM deposition in the mesangial region and the prognosis of IgA nephropathy：a single-centre retrospective study [J ] . BMC Nephrol ， 2024 ， 25 （ 1 ）： 438 .

KNOPPOVA B ， REILY C ， MAILLARD N ， et al . The origin and activities of IgA1-containing immune complexes in IgA nephropathy [J ] . Front Immunol ， 2016 ， 7 ： 117 .

VAZQUEZ M I ， CATALAN-DIBENE J ， ZLOTNIK A . B cells responses and cytokine production are regulated by their immune microenvironment [J ] . Cytokine ， 2015 ， 74 （ 2 ）： 318 - 326 .

MAIXNEROVA D ， EL-KAROUI K ， RIZK D V ， et al . The full-blown clinical presentation of IgA nephropathy [J ] . Nephrol Dial Transplant ， 2023 ， 38 （ Suppl. 2 ）：ii16-ii24.

WANG Y ， ZHANG Y ， CAI G ， et al . The flavonoid components and pharmacological effects of the flower of Abelmoschus manihot （L.） Medic：a review [J ] . J Ethnopharmacol ， 2021 ， 267 ： 113498 - 113507 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of enteral immune microecological nutrition combined with ω-3 fish oil fat emulsion for postoperative hepatocellular carcinoma resection

Efficacy and safety comparison of dupilumab versus thalidomide in the treatment of refractory prurigo nodularis in adults

Clinical observation of dupilumab in the treatment of severe asthma-COPD overlap

Advances in the clinical application and safety of bispecific antibodies for cancer therapy

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Related Author

ZHANG Ming

YAN Huaying

XU Dongping

WANG Jingjing

ZHANG Licheng

QI Yumei

ZHANG Jianbo

HU Lei

Related Institution

Dept. of Nutrition， Tianjin Third Central Hospital

Dept. of Gastrointestinal and Anorectal Surgery， Tianjin Third Central Hospital

Dept. of Pharmacy， Wuhan First Hospital

Dept. of Respiratory， Nantong Third People’s Hospital/Nantong Third Hospital Affiliated to Nantong University

School of Pharmaceutical Sciences， Wenzhou Medical University

⁰